Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cytomegalovirus (CMV) and BK virus (BKV) reactivation remain a challenge for post-kidney transplant recipients. CMV viremia can cause systemic inflammation and immune dysregulation, ultimately leading to allograft rejection. Meanwhile, BKV reactivation can directly damage renal tubular cells, resulting in nephropathy and graft loss. Pre-transplant viral screening of donors and recipients helps assess patient risk and allows for prophylactic treatment of those at high risk. However, immune profiling with lymphocyte subsets may enable more personalized immunosuppressive regimens and preemptive strategies to reduce viral reactivation after kidney transplantation. Existing literature highlights a possible connection between pre-transplant lymphocyte subset profiles and subsequent CMV and BKV viremia, emphasizing immune profiling as a potential biomarker for viral reactivation.
This is a retrospective study looking at 100 kidney transplant recipients in the University Malaya Medical Centre (UMMC) and the University Malaya Specialist Centre (UMSC) from 2021 and 2024. Pre-transplant lymphocyte subset and incidence of CMV and BKV viremia at 1, 3, and 6 months after kidney transplantation are recorded. Data are collected from the electronic medical record.
The data will be analysed using IBM SPSS Statistics v.24 (Chicago, IL, USA). Continuous variables will be summarized by descriptive statistics such as mean, median, standard deviation and interquartile range while categorical variables will be expressed as frequencies and percentages. Intragroup changes will be analyzed by using ANOVA test. For between-group comparisons, either Pearson Chi-square or Fisher’s exact test will be used for categorical variables, whilst independent t-test (parametric) or Mann-Whitney test/ Wilcoxon signed rank sum analysis (non-parameteric) will be performed for continuous variables. A two-tailed p value of less than 0.05 is considered to be statistically significant.
The incidence of CMV viremia is 11% in the first month after kidney transplant, 5.1% in month 3, and 9.1% in month 6. The incidence of BKV viremia is 1% in month 1, 0% in month 3, and 2% in month 6. Overall, there are no statistically significant differences in lymphocyte subsets between patients who did or did not develop CMV and BKV viremia at months 1, 3, and 6 post-transplant.
The study showed limited evidence for a strong relationship between lymphocyte subsets and CMV and BKV viremia. However, in the setting of low BKV and moderate CMV burden, this may limit the power to detect clinical significance.
This abstract was previously presented at the Malaysian Society of Nephrology (MSN) meeting, and its re-submission is permitted by the original meeting organizers.
